## Monobind Inc.
Lake Forest, CA 92630, USA

## AccuBind
### ELISA Microwells

## D-Dimer Test System
### Product Code: 12025-300

## 1.0 INTRODUCTION

**Intended Use:** The Quantitative Determination of D-Dimer Concentration in Human Plasma and Serum by a Microplate Enzyme Immunoassay, Colorimetric

## 2.0 SUMMARY AND EXPLANATION OF THE TEST

D-Dimer is the term for the cross-linked dimer of fibrinogen degradation product (FDP) D. After fibrinogen is formed in a blood clot, it is broken down through a series of steps so that it can be cleared from the body. D-Dimer is the endpoint of this process which makes its elevation a useful marker for activation of the coagulation and fibrinolytic systems.[1]

D-Dimer concentration may be determined by a blood test to help diagnose thrombosis. Since its introduction in the 1990s, it has become an important test performed in patients with suspected thrombotic disorders. While a negative result practically rules out thrombosis, a positive result may indicate thrombosis but does not definitively rule out other potential causes.[1] Its main use, therefore, is to exclude thromboembolic disease where the probability is low. Additionally, the D-Dimer test can be used in the diagnosis of disseminated intravascular coagulation.[1]

In general circumstances, a D-Dimer value under 500 ng/ml fibrin equivalence units (FEU) excludes deep vein thrombosis (DVT), pulmonary embolism (PE) and other venous thromboembolism (VTE). However, baseline D-Dimer levels increase with age and during pregnancy so modified cut-off values should be implemented for these types of patients to minimize false-positive results.[2-3]

Monitoring D-Dimer levels has become increasingly important as a positive result is indicative of an increased mortality risk. Specifically, detecting high levels of D-Dimer in cancer and pulmonary infection patients is important. VTE is the second highest cause of death in patients with cancer while significant increases in D-Dimer have been linked to higher mortality in those suffering from lung diseases such as COVID-19.[4-6]

The D-Dimer AccuBind® Test System is a quantitative test designed to be sensitive across a wide range of D-Dimer values. The reagents utilize monoclonal mouse antibodies to create a sandwich complex via a simple, fast, and user-friendly protocol.

## 3.0 PRINCIPLE

**Immunoenzymometric sequential assay (TYPE 4):**
The essential reagents required for an immunoenzymometric assay include high affinity and specificity antibodies (enzyme and immobilized), with different and distinct epitope recognition, **in excess,** and native antigen.

Upon mixing assay buffer and a serum containing the native antigen, reaction results between the native antigen and the coated antibody, forming an antibody-antigen complex. This interaction is illustrated below:

$$Ag + Ab_{(C)} \underset{k_{-a}}{\overset{k_a}{\rightleftharpoons}} AgAb_{(C)}$$

$Ab_{(C)}$ = Coated Antibody (Excess Quantity)
$Ag$ = Native Antigen (Variable Quantity)
$AgAb_{(c)}$ = Antigen-Antibody complex (Variable Quant.)
$k_a$ = Rate Constant of Association
$k_{-a}$ = Rate Constant of Disassociation

After a suitable incubation period, the antibody-antigen bound fraction is separated from unbound antigen by decantation or aspiration. Another antibody (directed at a different epitope) labeled with an enzyme is added. Another interaction occurs to form an enzyme labeled antibody-antigen-coated-antibody sandwich complex on the surface of the wells.

$$AgAb_{(C)} + Ab_{(Enz)} \underset{k_{-a}}{\overset{k_a}{\rightleftharpoons}} Ab_{(Enz)}AgAb_{(C)}$$

$AgAb_{(c)}$ = Antigen-Antibody complex (Variable Quant.)
$Ab_{(Enz)}$ = Enzyme-labeled Antibody (Excess Quant.)
$Ab_{(Enz)}AgAb_{(C)}$ = Sandwich complex (Variable Quant.)
$k_a$ = Rate Constant of Association
$k_{-a}$ = Rate Constant of Disassociation

After another incubation period, the excess enzyme-labeled antibody is separated by washing. The remaining complex is then quantified by addition of substrate that reacts with bound enzyme. The amount of antigen is directly related to the amount of substrate converted by the enzyme.

## 4.0 REAGENTS

**Materials Provided:**

**A. D-Dimer Calibrators – 1 ml/vial - Icons A-F**
Six (6) vials of references for D-Dimer Antigen at levels of 0(**A**), 100(**B**), 400(**C**), 1500(**D**), 4000(**E**) and 10000(**F**) ng/ml FEU. Store at 2-8°C. A preservative has been added.

**B. D-Dimer Control – 1 ml/vial – Icon M**
One (1) vial of reference control for D-Dimer. Store at 2-8°C. A preservative has been added.

**C. Assay Buffer – 12 ml/vial - Icon Ⓑ**
One (1) vial containing buffer, dye, and preservatives. Store at 2-8°C.

**D. D-Dimer Enzyme Reagent – 13 ml/vial - Icon Ⓔ**
One (1) vial containing Enzyme (HRP) labeled Anti-D-Dimer monoclonal mouse IgG in buffer, dye, and preservative. Store at 2-8°C.

**E. D-Dimer Antibody Coated Plate – 96 wells - Icon**
One 96-well microplate coated with Anti-D-Dimer monoclonal mouse IgG and packaged in an aluminum bag with a drying agent. Store at 2-8°C.

**F. Wash Solution Concentrate – 20 ml/vial - Icon**
One (1) vial containing a surfactant in buffered saline. A preservative has been added. Store at 2-8°C.

**G. Substrate A – 7 ml/vial - Icon S^A**
One (1) vial containing tetramethylbenzidine (TMB) in buffer. Store at 2-8°C.

**H. Substrate B – 7 ml/vial - Icon S^B**
One (1) vial containing hydrogen peroxide ($H_2O_2$) in buffer. Store at 2-8°C.

**I. Stop Solution – 8 ml/vial - Icon (STOP)**
One (1) vial containing a strong acid (1N HCl). Store at 2-30°C.

**J. Product Instructions.**

**Note 1:** Do not use reagents beyond the kit expiration date.
**Note 2:** Avoid extended exposure to heat and light. **Opened reagents are stable for sixty (60) days when stored at 2-8°C. Kit and component stability are identified on the label.**
**Note 3:** Above reagents are for a single 96-well microplate

**4.1 Required But Not Provided:**
1. Pipette(s) capable of delivering 0.025 and 0.050ml (25 & 50µl) volumes with a precision of better than 1.5%.
2. Dispenser(s) for repetitive deliveries of 0.100 and 0.350ml (100 & 350µl) volumes with a precision of better than 1.5%.
3. Microplate washers or a squeeze bottle (optional).
4. Microplate Reader with 450nm and 620nm wavelength absorbance capability.
5. Absorbent Paper for blotting the microplate wells.
6. Plastic wrap or microplate cover for incubation steps.
7. Vacuum aspirator (optional) for wash steps.
8. Timer.
9. Quality control materials

## 5.0 PRECAUTIONS

*For In Vitro Diagnostic Use*
**Not for Internal or External Use in Humans or Animals**

All products that contain human serum have been found to be non-reactive for Hepatitis B Surface Antigen, HIV 1&2 and HCV Antibodies by FDA licensed reagents. Since no known test can offer complete assurance that infectious agents are absent, all human serum products should be handled as potentially hazardous and capable of transmitting disease. Good laboratory procedures for handling blood products can be found in the Center for Disease Control / National Institute of Health, "Biosafety in Microbiological and Biomedical Laboratories," 2nd Edition, 1988, HHS Publication No. (CDC) 88-8395.

**Safe Disposal of kit components must be according to local regulatory and statutory requirement.**

## 6.0 SPECIMEN COLLECTION AND PREPARATION

The specimens shall be blood plasma (EDTA, Li-Heparin, or Citrate may be used as anticoagulant) or serum in type and the usual precautions in the collection of venipuncture samples should be observed. In order to avoid erroneous results, blood samples should be centrifuged within 15 minutes of collection and the plasma or serum should be removed from the red cells immediately.

Plasma samples may be refrigerated at 2-8°C for a maximum period of three (3) days. Serum samples may be refrigerated at 2-8°C for up to fourteen (14) days. If the specimen(s) cannot be assayed within this time, the sample(s) may be stored at temperatures of -20°C for up to 30 days. Avoid use of contaminated devices. Avoid repetitive freezing and thawing. When assayed in duplicate, 0.05 ml (50µl) of the specimen is required.

## 7.0 QUALITY CONTROL

Each laboratory should assay controls at levels in the low, normal and elevated range for monitoring assay performance. These controls should be treated as unknowns and values determined in every test procedure performed. Quality control charts should be maintained to follow the performance of the supplied reagents. Pertinent statistical methods should be employed to ascertain trends. Significant deviation from established performance can indicate unnoticed change in experimental conditions or degradation of kit reagents. Fresh reagents should be used to determine the reason for the variations.

## 8.0 REAGENT PREPARATION

1. **Wash Buffer**
Dilute contents of wash solution concentrate to 1000ml with distilled or deionized water in a suitable storage container. Store diluted buffer at 2-30°C for up to 60 days.
2. **Working Substrate Solution** – Stable for one year.
Pour the contents of the amber vial labeled Substrate 'A' into the clear vial labeled Substrate 'B'. Place the yellow cap on the clear vial for easy identification. Mix and label accordingly. Store at 2 - 8°C.

*Note1: Do not use the working substrate if it looks blue.*
*Note 2: Do not use reagents that are contaminated or have bacteria growth.*

## 9.0 TEST PROCEDURE

*Before proceeding with the assay, bring all reagents, serum reference calibrators and controls to room temperature (20-27℃).*

**\*\*Test Procedure should be performed by a skilled individual or trained professional\*\***

1. Format the microplate wells for each serum reference calibrator, control and patient specimen to be assayed. (Duplicate is recommended) **Replace any unused microwell strips back into the aluminum bag, seal and store at 2-8°C**
2. Pipette 0.025 ml (25µl) of the appropriate serum reference calibrator, control or specimen into the assigned well.
3. Add 0.100 ml (100µl) of Assay Buffer to all wells.
4. Swirl the microplate gently for 20-30 seconds to mix and cover.
5. Incubate 20 minutes at room temperature
6. Discard the contents of the microplate by decantation or aspiration. If decanting, blot the plate dry with absorbent paper.
7. Add 0.350ml (350µl) of wash buffer (see Reagent Preparation Section), decant (tap and blot) or aspirate. Repeat two (2) additional times for a total of three (3) washes. **An automatic or manual plate washer can be used. Follow the manufacturer's instruction for proper usage. If a squeeze bottle is employed, fill each well by depressing the container (avoiding air bubbles) to dispense the wash. Decant the wash and repeat two (2) additional times.**
8. Add 0.100 ml (100µl) of D-Dimer-Enzyme Reagent to all wells. **DO NOT SHAKE THE PLATE AFTER ENZYME ADDITION**
9. Incubate 20 minutes at room temperature.
10. Wash the wells three (3) times by following steps 6 and 7 as above.
11. Add 0.100 ml (100µl) of working substrate solution to all wells (see Reagent Preparation Section). **Always add reagents in the same order to minimize reaction time differences between wells**
**DO NOT SHAKE THE PLATE AFTER SUBSTRATE ADDITION**
12. Incubate at room temperature for fifteen (15) minutes.
13. Add 0.050ml (50µl) of stop solution to each well and gently mix for 15-20 seconds. **Always add reagents in the same order to minimize reaction time differences between wells**
14. Read the absorbance in each well at 450nm (using a reference wavelength of 620-630nm to minimize well imperfections) in a microplate reader. **The results should be read within thirty (30) minutes of adding the stop solution.**

## 10.0 CALCULATION OF RESULTS

A dose response curve is used to ascertain the concentration of D-Dimer in unknown specimens.
1. Record the absorbance obtained from the printout of the microplate reader as outlined in Example 1.
2. Plot the absorbance for each duplicate serum reference versus the corresponding D-Dimer concentration in ng/ml on linear graph paper (do not average the duplicates of the serum references before plotting).
3. Draw the best-fit curve through the plotted points.
4. To determine the concentration of D-Dimer for an unknown, locate the average absorbance of the duplicates for each unknown on the vertical axis of the graph, find the intersecting point on the curve, and read the concentration (in ng/ml) from the horizontal axis of the graph (the duplicates of the unknown may be averaged as indicated). In the following example, the average absorbance (1.761) intersects the dose response curve at (3315 ng/ml) D-Dimer concentration (See Figure 1).

**Note:** Computer data reduction software designed for ELISA assays may also be used for the data reduction. If such software is utilized, the validation of the software should be ascertained.

### EXAMPLE 1

| Sample I.D. | Well Number | Abs (A) | Mean Abs (B) | Value (ng/ml) |
|---|---|---|---|---|
| Cal A | A1 | 0.005 | 0.004 | 0 |
| | B1 | 0.003 | | |
| Cal B | C1 | 0.066 | 0.065 | 100 |
| | D1 | 0.065 | | |
| Cal C | E1 | 0.290 | 0.299 | 400 |
| | F1 | 0.308 | | |
| Cal D | G1 | 0.968 | 0.977 | 1500 |
| | H1 | 0.986 | | |
| Cal E | A2 | 2.027 | 1.982 | 4000 |
| | B2 | 1.938 | | |
| Cal F | C2 | 2.881 | 2.848 | 10000 |

| | | | | |
|---|---|---|---|---|
| | D2 | 2.815 | | |
| Ctrl 1 | E2 | 0.094 | 0.098 | **146** |
| | F2 | 0.101 | | |
| Ctrl 2 | G2 | 0.951 | 0.965 | **1476** |
| | H2 | 0.979 | | |
| Patient | A3 | 1.704 | 1.761 | **3315** |
| | B3 | 1.807 | | |

*The data presented in Example 1 and Figure 1 are for illustration only and **should not** be used in lieu of a dose response curve prepared with each assay.

**Figure 1**



## 11.0  Q.C. PARAMETERS

In order for the assay results to be considered valid the following criteria should be met:
1. The absorbance (OD) of calibrator 'F' should be > 1.3.
2. Four out of six quality control pools should be within the established ranges.

## 12.0  RISK ANALYSIS

*The MSDS and Risk Analysis Form for this product are available on request from Monobind Inc.*

**12.1 Assay Performance**
1. It is important that the time of reaction in each well is held constant to achieve reproducible results.
2. Pipetting of samples should not extend beyond ten (10) minutes to avoid assay drift.
3. Highly lipemic, hemolyzed or grossly contaminated specimen(s) should not be used.
4. If more than one (1) plate is used, it is recommended to repeat the dose response curve.
5. The addition of substrate solution initiates a kinetic reaction, which is terminated by the addition of the stop solution. Therefore, the substrate and stop solution should be added in the same sequence to eliminate any time-deviation during reaction.
6. Plate readers measure vertically. Do not touch the bottom of the wells.
7. Failure to remove adhering solution adequately in the aspiration or decantation wash step(s) may result in poor replication and spurious results.
8. Use components from the same lot. No intermixing of reagents from different batches.
9. Patient specimens with D-Dimer concentrations above 10,000 ng/ml may be diluted 1:10 with the "0" calibrator matrix or other normal serum containing low levels of D-Dimer (< 500 ng/ml) and re-assayed. The sample's concentration is obtained by multiplying the result by the dilution factor and adding the D-Dimer concentration of the diluent used.
10. Accurate and precise pipetting, as well as following the exact time and temperature requirements prescribed are essential. Any deviation from Monobind IFU may yield inaccurate results.
11. All applicable national standards, regulations and laws, including, but not limited to, good laboratory procedures, must be strictly followed to ensure compliance and proper device usage.
12. It is important to calibrate all the equipment e.g. Pipettes, Readers, Washers and/or the automated instruments used with this device, and to perform routine preventative maintenance.
13. Risk Analysis- as required by CE Mark IVD Directive 98/79/EC - for this and other devices, made by Monobind, can be requested via email from Monobind@monobind.com.

## 12.2 Interpretation

1. *Measurements and interpretation of results must be performed by a skilled individual or trained professional.*
2. Laboratory results alone are only one aspect for determining patient care and should not be the sole basis for therapy, particularly if the results conflict with other determinants.
3. The reagents for the test system have been formulated to eliminate maximal interference; however, potential interaction between rare serum specimens and test reagents can cause erroneous results. Heterophilic antibodies often cause these interactions and have been known to be problems for all kinds of immunoassays (Boscato LM, Stuart MC. 'Heterophilic antibodies: a problem for all immunoassays' Clin. Chem. 1988:3427-33). For diagnostic purposes, the results from this assay should be in combination with clinical examination, patient history and all other clinical findings.For valid test results, adequate controls and other parameters must be within the listed ranges and assay requirements.
4. If test kits are altered, such as by mixing parts of different kits, which could produce false test results, or if results are incorrectly interpreted, Monobind shall have no liability.
5. If computer controlled data reduction is used to interpret the results of the test, it is imperative that the predicted values for the calibrators fall within 10% of the assigned concentrations.
6. **A D-Dimer value alone is not at diagnostic value** and should only be used in conjunction with other clinical manifestations (observations) and diagnostic procedures.

## 13.0  EXPECTED RANGES OF VALUES

The expected D-Dimer levels for exclusion of thrombosis in plasma samples were obtained from published literature.[2-3, 7] There is general consensus for the following data.

**Table 1: Expected Plasma D-Dimer Levels**

| Patient Age | D-Dimer Level to Exclude Thrombosis |
|---|---|
| <50 years | <500 ng/ml FEU |
| >50 years | <Age x 10 ng/ml FEU |

To obtain a reference range for serum samples, D-Dimer levels were measured by the D-Dimer AccuBind® Test System in apparently normal adults of different age groups. The values obtained are shown in Table 2.

**Table 2: Serum D-Dimer Ranges**

| Patient Age (years) | N | Average (ng/ml FEU) | Highest (ng/ml FEU) | Lowest (ng/ml FEU) |
|---|---|---|---|---|
| <50 | 23 | 326 | 1244 | 137 |
| 50-59 | 19 | 486 | 1375 | 161 |
| 60-69 | 11 | 467 | 859 | 180 |
| 70-79 | 3 | 440 | 808 | 230 |
| 80+ | 3 | 878 | 1206 | 311 |

It is important to keep in mind that establishment of a range of values, which can be expected to be found by a given method for a population of "normal" persons, is dependent upon a multiplicity of factors: the specificity of the method, the population tested and the precision of the method in the hands of the analyst. For these reasons, each laboratory should depend upon the range of expected values established by the manufacturer only until an in-house range can be determined by the analysts using the method with a population indigenous to the area in which the laboratory is located.

## 14.0  PERFORMANCE CHARACTERISITICS

**14.1  Precision**
The intra-assay precision of the D-Dimer AccuBind® ELISA test system was determined by measuring sixteen (16) replicates of three levels of patient control pools on the same assay run. The results are shown in Table 3.

**Table 3: Intra-assay Precision**

| Sample | N | Mean (ng/ml) | σ | CV% |
|---|---|---|---|---|
| Control 1 | 16 | 200 | 10.2 | 5.1 |
| Control 2 | 16 | 1934 | 51.5 | 2.7 |
| Control 3 | 16 | 4237 | 159.8 | 3.8 |

The inter-assay precision (total precision) of the D-Dimer AccuBind® ELISA test system was determined by measuring three levels of patient control pools on three different kits throughout the course of two months. The results are given in Table 4.

**Table 4: Inter-assay Precision**

| Sample | N | Mean (ng/ml) | σ | CV% |
|---|---|---|---|---|
| Control 1 | 24 | 147 | 9.3 | 6.4 |
| Control 2 | 24 | 1492 | 96.3 | 6.5 |
| Control 3 | 24 | 3352 | 174.0 | 5.2 |

**14.2  Sensitivity**
The D-Dimer AccuBind® ELISA test system has a sensitivity of 4.76 ng/ml. The sensitivity was ascertained by determining the variability of the 0 ng/ml calibrator and using the 2σ (95% certainty) statistics to calculate the minimum dose.

**14.3  Accuracy**
**14.3.1 Linearity**
The linearity of the D-Dimer AccuBind® ELISA Test System was tested by serially diluting several human plasma and serum samples containing high levels of D-Dimer (up to 11,000 ng/ml) with the "0 ng/ml" serum reference. The observed values were plotted against the expected values and the test system was determined to have excellent linearity up to 11,065 ng/ml with a slope of 1.004 and a correlation factor ($R^2$) of 0.994.
**14.3.2 Recovery**
Several human plasma and serum samples containing low levels of D-Dimer (100-700 ng/ml) were spiked with 100, 400, 1200, 4000, and 8000 ng/ml of D-Dimer and assayed on the D-Dimer AccuBind® ELISA Test System. The system demonstrated excellent recovery with all observed values falling within 15% of the expected values.
**14.4  Specificity**
The following substances were tested on the D-Dimer AccuBind® ELISA test system to determine interference and cross-reactivity. The results are tabulated below.

| Substance | Cross Reactivity | Concentration |
|---|---|---|
| D-Dimer | 1.0000 | ---- |
| Fibrinogen | < 0.0001 | 4mg/ml |
| Plasminogen | < 0.0001 | 150ng/ml |
| Angiostatin | < 0.0001 | 150ng/ml |
| tPA | < 0.0001 | 150ng/ml |
| PAI1 | < 0.0001 | 150ng/ml |

## 15.0  REFERENCES

1. Johnson ED, Schell JC, Rodgers GM. The D-Dimer assay. *American Journal of Hematology*. **94**: 833-839. 2019. doi:10.1002/ajh.25482
2. Urban K, Kirley K, Stevermer JJ. It's time to use an age-based approach to D-Dimer. *The Journal of Family Practice*. **63**(3): 155-158. 2014
3. Garcia IG, Cañadas PP, Uriarte JM, Izquierdo OG, Perez MAJ, Romualdo LGG. D-Dimer during pregnancy: establishing trimester-specific reference intervals.*Scandinavian Journal of Clinical and Laboratory Investigation*. **79**(6): 439-442. 2018. https://doi.org/10.1080/00365513.2018.1488177
4. Weitz JI, Fredenburgh JC, Eikelboom JW, A Test in Context: D-Dimer. *Journal of the American College of Cardiology* **70**(19): 2411-2420. 2017.
5. Zhang L, Yan X, Fan Q, Liu H, Liu X, Liu Z, Zhang Z. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemost.**18**(6):1324-1329. 2020 doi:10.1111/jth.14859.
6. Velavan, Thirumalaisamy P.; Meyer, Christian G. Mild versus severe COVID-19: laboratory markers" *International Journal of Infectious Diseases*. doi:10.1016/j.ijid.2020.04.061. Retrieved 25 April 2020.
7. Harper PL, Theakston E, Ahmed J, Ockelford P. D-Dimer concentration increases with age reducing the clinical value of the D-Dimer assay in the elderly. *Internal Medicine Journal* **37**: 607-613. 2007

| Size | | 96(A) | 192(B) |
|---|---|---|---|
| Reagent (fill) | A) | 1ml set | 1ml set |
| | B) | 1ml | 1ml |
| | C) | 12ml | 2 (12ml) |
| | D) | 13ml | 2 (13ml) |
| | E) | 1 plate | 2 plates |
| | F) | 1 (20ml) | 1 (20ml) |
| | G) | 1 (7ml) | 2 (7ml) |
| | H) | 1 (7ml) | 2 (7ml) |
| | I) | 1 (8ml) | 2 (8ml) |

**Glossary of Symbols**
(EN 980/ISO 15223)

| | | |
|---|---|---|
| **IVD** In Vitro - Diagnostic Medical Device | 2°[8°] Temperature Limitation Storage Condition (2-8° C) | Consult Instructions for Use |
| **REF** Catalogue Number | Σ Contains Sufficient Test for Σ | **LOT** Batch Code |
| Used By (Expiration Day) | Date of Manufacturer | Manufacturer |
| **EC REP** Authorized Rep in European Country | CE European Conformity | |